1. Academic Validation
  2. Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory Activity

Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory Activity

  • ACS Med Chem Lett. 2020 Oct 16;11(12):2389-2396. doi: 10.1021/acsmedchemlett.0c00344.
Ramsay E Beveridge 1 Heidi Ackerly Wallweber 2 Avi Ashkenazi 2 Maureen Beresini 2 Kevin R Clark 2 Paul Gibbons 2 Elise Ghiro 1 Susan Kaufman 2 Alexandre Larivée 1 Melissa Leblanc 1 Jean-Philippe Leclerc 1 Alexandre Lemire 1 Cuong Ly 2 Joachim Rudolph 2 Jacob B Schwarz 2 Sanjay Srivastava 1 Weiru Wang 2 Liang Zhao 1 Marie-Gabrielle Braun 2
Affiliations

Affiliations

  • 1 Paraza Pharma Inc., 2525 Ave. Marie-Curie, Montreal, QC, Canada H4S 2E1.
  • 2 Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States.
Abstract

Amino-quinazoline BRaf kinase inhibitor 2 was identified from a library screen as a modest inhibitor of the unfolded protein response (UPR) regulating potential Anticancer target IRE1α. A combination of crystallographic and conformational considerations were used to guide structure-based attenuation of BRaf activity and optimization of IRE1α potency. Quinazoline 6-position modifications were found to provide up to 100-fold improvement in IRE1α cellular potency but were ineffective at reducing BRaf activity. A salt bridge contact with Glu651 in IRE1α was then targeted to build in selectivity over BRaf which instead possesses a histidine in this position (His539). Torsional angle analysis revealed that the quinazoline hinge binder core was ill-suited to accommodate the required conformation to effectively reach Glu651, prompting a change to the thienopyrimidine hinge binder. Resulting analogues such as 25 demonstrated good IRE1α cellular potency and imparted more than 1000-fold decrease in BRaf activity.

Figures
Products